Human Vaccines and Immunotherapeutics

Aims & Scope

Human Vaccines & Immunotherapeutics is the only peer-reviewed journal focused on vaccines and immunotherapeutics for humans.

The journal publishes 12 issues per year, mostly as original research articles and reviews, and also features commentaries and news updates.

Also included are Special Features of articles and reviews on a focused theme of high interest as well as Special Issues devoted entirely to one such topic or to articles from prestigious international conferences.

The journal is fully indexed with a broad and distinguished international panel of Editorial Board members and Associate Editors Editorial Board.

The journal enjoys relatively rapid turnaround time from submission to acceptance to publication.

Human Vaccines & Immunotherapeutics (HV&I) provides a platform for presenting and discussing cutting-edge research and developments in vaccinology and immunotherapy.

Our journal brings together scientists, physicians, public health practitioners, and analysts working in the areas of: -research and development of novel vaccines and immunotherapeutics -experimental vaccines and novel approaches in vaccination and immunotherapy -vaccines and immunotherapeutics for treating non-infectious diseases, e.g., cancer -preclinical studies and clinical trials -licensed products and their use in the field -impact of licensed vaccines and Immunotherapeutics on disease -safety and perceptions of licensed vaccines -prevention and treatment in the developing world -epidemiology and pharmaco-economics

Metrics & Ranking

Abstracting & Indexing

Journal is indexed in leading academic databases, ensuring global visibility and accessibility of our peer-reviewed research.

• Scopus
• Google Scholar
• Directory of Open Access Journals (DOAJ)
• Web of Science
• Medline
• PubMed

Subjects & Keywords

Journal’s research areas, covering key disciplines and specialized sub-topics in Immunology and Microbiology, Medicine and Pharmacology, Toxicology and Pharmaceutics, designed to support cutting-edge academic discovery.

Licensing & Copyright

This journal operates under an Open Access model. Articles are freely accessible to the public immediately upon publication. The content is licensed under a Creative Commons Attribution 4.0 International License (CC BY 4.0), allowing users to share and adapt the work with proper attribution.

Copyright remains with the author(s), and no permission is required for non-commercial use, provided the original source is cited.

Policy Links

This section provides access to essential policy documents, guidelines, and resources related to the journal’s publication and submission processes.

• Aims scope
• Homepage
• Oa statement
• Author instructions
• License terms
• Review url
• Board url
• Copyright url
• Plagiarism url
• Preservation url
• Apc url
• License

Plagiarism Policy

This journal follows a plagiarism policy. All submitted manuscripts are screened using reliable plagiarism detection software to ensure originality and academic integrity. Authors are responsible for proper citation and acknowledgment of all sources, and any form of plagiarism, including self-plagiarism, will not be tolerated.

For more details, please refer to our official: Plagiarism Policy.

APC Details

The journal’s Article Processing Charge (APC) policies support open access publishing in Immunology and Microbiology, Medicine and Pharmacology, Toxicology and Pharmaceutics, ensuring accessibility and quality in research dissemination.

This journal requires an Article Processing Charge (APC) to support open access publishing, covering peer review, editing, and distribution. The current APC is 5,085.00 AUD. Learn more.

Explore journals without APCs for alternative publishing options.

Most Cited Articles

The Most Cited Articles section features the journal's most impactful research, based on citation counts. These articles have been referenced frequently by other researchers, indicating their significant contribution to their respective fields.

• Vaccine hesitancy

  Citation: 1712

  Authors: Eve, Caroline, Maryse, Paul, Réal, Julie A.

• Social media and vaccine hesitancy: new updates for the era of COVID-19 and globalized infectious diseases

  Citation: 876

  Authors: Neha, Eric A., Hourmazd, Keith

• The use of the health belief model to assess predictors of intent to receive the COVID-19 vaccine and willingness to pay

  Citation: 625

  Authors: Li Ping, Haridah, Pooi-Fong, Hai Yen, Sazaly

• Measuring trust in vaccination: A systematic review

  Citation: 544

  Authors: Heidi J., Richard M., Caitlin, Elisabeth, Zachary, Will S., Pauline

• COVID-19 vaccination intention in the UK: results from the COVID-19 vaccination acceptability study (CoVAccS), a nationally representative cross-sectional survey

  Citation: 498

  Authors: Susan M., Louise E., Julius, Richard, Megan, Hannah, G James, Nick

• PD-1 and PD-L1 in cancer immunotherapy: clinical implications and future considerations

  Citation: 468

  Authors: Yongshuai, Ming, Hong, Yuanyang

• COVID-19, an emerging coronavirus infection: advances and prospects in designing and developing vaccines, immunotherapeutics, and therapeutics

  Citation: 399

  Authors: Kuldeep, Khan, Ruchi, Maryam, Yashpal Singh, Karam Pal, Wanpen

• RTS,S/AS01 vaccine (Mosquirixâ„¢): an overview

  Citation: 375

  Authors: Matthew B.

• Pembrolizumab (Keytruda)

  Citation: 368

  Authors: Gerry, Thomas C. C., Joanne W., Eric, Yok-Lam

• Advances in aluminum hydroxide-based adjuvant research and its mechanism

  Citation: 348

  Authors: Peng, Yening, Zhongyu